Alimera Sciences Inc (ALIM) 1.72 $ALIM Alimera Sciences

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alimera Sciences Inc (ALIM) 1.72 $ALIM

Alimera Sciences to Present at the LD Micro Invitational Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the LD Micro Invitational Conference, to be held June 7 - 9, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The Company's presentation will take place Wednesday, June 8, 2016 at 8:30 AM Pacific Time.
ALIM: 1.72 (+0.03)

Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien(R) At 12 Months
GlobeNewswire - Mon May 23, 3:00PM CDT
Despite other prior treatments, improvements in visual acuity and retinal thickness were seen in the majority of patients
ALIM: 1.72 (+0.03)

Alimera Sciences to Present at the UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 6:30AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the UBS Global Healthcare Conference, to be held May 23 - 25, 2016 at the The Grand Hyatt in New York City, New York. The Company's presentation will take place Monday, May 23, 2016 at 11:30 AM Eastern Time.
ALIM: 1.72 (+0.03)

Alimera Sciences' ILUVIEN(R) Data Presented at SFO 2016
GlobeNewswire - Wed May 11, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from six ILUVIEN post marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10.
ALIM: 1.72 (+0.03)

Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO
PR Newswire - Fri May 06, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from seven ILUVIEN® post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, May 1-5.
ALIM: 1.72 (+0.03)

Alimera Sciences reports 1Q loss
Automated Insights - Wed May 04, 6:48PM CDT
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Wednesday reported a loss of $11.1 million in its first quarter.
ALIM: 1.72 (+0.03)

Alimera Sciences Announces First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:23PM CDT
-- First quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN(R) sales in the U.S.
ALIM: 1.72 (+0.03)

Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE - Wed Apr 27, 8:02AM CDT
DALLAS, TX / ACCESSWIRE / April 27, 2016 / Stonegate Capital Partners initiates research coverage on Alimera Sciences, Inc. (NASDAQ: ALIM).
ALIM: 1.72 (+0.03), REGN: 372.03 (-9.05)

Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016
GlobeNewswire - Tue Apr 26, 8:58AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended March 31st, 2016, at the close of the financial markets on May 4, 2016.
ALIM: 1.72 (+0.03)

New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 10.26 (-0.50), ALIM: 1.72 (+0.03), ARES: 13.91 (+0.17), AXTA: 27.90 (+0.02), ARNA: 1.99 (-0.07)

New Strong Sell Stocks for April 18th
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 6:42AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
CRME: 4.96 (-0.38), ALIM: 1.72 (+0.03), CAR: 32.86 (-1.34), BAC: 13.83 (-0.36), CWT: 31.91 (+0.45)

New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 59.92 (-0.61), ALIM: 1.72 (+0.03), AMD: 4.32 (-0.20), CWT: 31.91 (+0.45), ATRS: 1.05 (-0.04)

New Strong Sell Stocks for March 16th
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 7:29AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
FITB: 18.53 (-0.20), CECE: 8.29 (-0.31), ALIM: 1.72 (+0.03), FBC: 24.00 (-0.08), FCFS: 47.00 (+0.18)

Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Wed Mar 02, 6:48PM CST
-- Annual revenue increased 167% for 2015 compared to 2014
ALIM: 1.72 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 156

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 364

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 294

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 356

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 40

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 107

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Rigetti Computing's Impressive Growth and Strategic Moves Ahead

Updated Category News Views 244

Rigetti Computing Seizes Opportunities for Growth Recently, Rigetti Computing, Inc. (Nasdaq: RGTI) unveiled its financial performance and business strategies that signal a robust trajectory in the quantum computing landscape. Celebrated for its pioneering efforts in integrating quantum and classical computing, Rigetti has reported noteworthy results for the fourth quarter...

Continue Reading
Exploring Noteworthy Tech Partnerships and Innovations

Updated Category News Views 281

Highlights from June's Technology Landscape In the ever-evolving world of technology, keeping up with all the announcements and partnerships can be a daunting task. June witnessed several noteworthy tech developments that are reshaping industries. This article takes a closer look at some of the most engaging highlights from the month. Key Announcements Chainlink and...

Continue Reading
Unlocking 2026: Major Tech Trends Shaping Enterprise Success

Updated Category News Views 262

Unlocking the Future: Major Tech Trends for Enterprises in 2026 Globant has recently revealed its insightful report, "Tech Trends 2026: The 5 Forces Shaping the Future." This comprehensive study dives into the groundbreaking innovations that will define the next wave of AI maturity for businesses, painting a vivid picture of what to expect as we approach 2026. Today,...

Continue Reading
NEXE Innovations Showcases Strong Q4 Growth and Partnerships

Updated Category News Views 215

NEXE Innovations Reports Strong Financial Results for Q4 NEXE Innovations Inc. (TSX.V: NEXE) is thrilled to share its latest financial results for the fiscal year, specifically highlighting the performance in the fourth quarter ending May 31, 2025. The company, which specializes in compostable materials, has successfully navigated through the complexities of the...

Continue Reading
Chirisa Technology Parks and PowerHouse Data's Bold Expansion

Updated Category News Views 246

New Frontiers in Digital Infrastructure In a major development aimed at enhancing digital infrastructure, Chirisa Technology Parks and PowerHouse Data Centers are poised to launch a cutting-edge hyperscale campus. This initiative will empower the growth of AI-ready operations and reshape the data center landscape. What’s notable here isn’t just the tech; it’s also...

Continue Reading